miR-34a在复发-缓解型多发性硬化患者血清中表达情况研究  

miR-34a expression in the serum of relapsing and remitting multiple sclerosis

作　　者：代慧宇 

机构地区：[1]哈尔滨医科大学附属第四医院神经内科,黑龙江哈尔滨150000

出　　处：《临床军医杂志》2017年第5期478-480,484,共4页Clinical Journal of Medical Officers

摘　　要：目的检测复发-缓解型多发性硬化患者在急性复发期及缓解期外周血血清miR-34a的表达情况,探讨其作为新的血清标记物的可能性,以及其血清表达情况与疾病活动的关系。方法选取2014年1月至2015年12月在哈尔滨医科大学附属第四医院神经内科就诊的复发-缓解型多发性硬化患者20例为观察组,患者均处于急性复发期且近期未接受任何治疗;患者均接受随访,在缓解期未用药物治疗(免疫调节药物等)。同时,选取年龄、性别与观察组相匹配的20例健康人作为健康组。分别采集两组患者外周静脉血,提取血清总RNA,并对miR-34a进行RT-qPCR检测验证,对观察组急性复发期和缓解期、健康组分别进行多种microRNA的相对定量分析。结果 RT-qPCR检测结果显示,观察组急性复发期与健康组比较,血清中miR-34a的含量明显降低,对照组平均表达量约为观察组急性复发期的1.91倍,差异有统计学意义(P<0.05);miR-34a在观察组缓解期的血清表达与健康组比较,差异无统计学意义(P>0.05)。结论 miR-34a在复发-缓解型多发性硬化患者的急性复发期中表达降低,并可能具有作为复发-缓解型多发性硬化急性复发期诊断的血清生物标志物潜质。Objective To detect the expression of miR-34a in relapsing-remitting multiple sclerosis （RRMS）of peripheral blood serum in acute relapse phase and remission stage,investigate the possibility of it as a new serum markers and the relationship between the se- rum and active disease. Methods A retrospective study was performed on RRMS patients who were admitted from January 2014 to December 2015. The 20 RRMS patients in the acute and remit phase were divided into the observation group, patients were in acute and remit phase without any treatment ; all the patients were followed up and were not treated with medication（immunoregulatory medi- cation） during the period of relief. At the same time, another 20 healthy volunteers whose age and gender were matched with the ones in the observation group were selected in the healthy group. The total RNA from the cell-free serum samples were extracted, using RT- Qpcr assay to test the expression of miR-34a according to the results of preliminary experiments in order to screen differentially ex- pressed microRNAs as potential serum biomarkers for multiple sclerosis（MS） in the acute relapse group and the healthy group. Results Acute phase MS group showed an down-regulation of miR-34a, with an average fold change of 1.91 （ P 〈 0.05 ） ; there was no statis- tically significant difference of miR-34a between observation group in relapsing period and healthy group （ P 〉 0. 05 ）. Conclusion miR-34a is down-regulated in the serum of acute phase MS patients,it may serve as a potential serum biomarker for multiple sclerosis.

关 键 词：多发性硬化 MIR-34A 血清标记物 急性复发期 缓解期 

分 类 号：R744.51[医药卫生—神经病学与精神病学]